Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01143389 · ClinicalTrials.gov registry record · Phase 2
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
A Phase 2 study, sponsored by Price Vision Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
NCT01143389: Completed Phase 2 study, sponsored by Price Vision Group.
NCT01143389 is a Phase 2 study that has completed, run by Price Vision Group. The registered enrollment target is 510 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01143389, a Phase 2 study, has completed, sponsored by Price Vision Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
Primary Outcome
Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.
Interventions
- DRUG Riboflavin
- DEVICE UVX light
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2010-05 |
| Est. Completion | 2017-08-30 |
| Phase | Phase 2 |
What the finished NCT01143389 record still lists
NCT01143389 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (283% higher).
The record links to 0 conditions, and to 2 interventions - of which Riboflavin is the first listed.
NCT01143389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01143389 about?
NCT01143389 is a clinical study titled "Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia". The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
What is the current status of trial NCT01143389?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2010-05. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT01143389?
The interventions under investigation include: Riboflavin (DRUG), UVX light (DEVICE).
Who is sponsoring clinical trial NCT01143389?
This trial is sponsored by Price Vision Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01143389's enrollment target sits among peer trials
510 68th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia